Log in

Relevant bibliographies by topics / Chronic myeloid leukaemia; Treatment / Journal articles

To see the other types of publications on this topic, follow the link: Chronic myeloid leukaemia; Treatment.

Journal articles on the topic 'Chronic myeloid leukaemia; Treatment'

Author: Grafiati

Published: 4 June 2021

Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chronic myeloid leukaemia; Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Egyed, Miklós, Balázs Kollár, Péter Rajnics, Éva Karádi, and András Matolcsi. "Imatinib treatment of our chronic myeloid leukemia patients." Orvosi Hetilap 149, no. 32 (2008): 1509–12. http://dx.doi.org/10.1556/oh.2008.28354.

Full text

Abstract:

A krónikus myeloid leukaemia a pluripotens haemopoeticus őssejt malignus klonális betegsége. A kórkép genetikai háttere a t(9;22) (Philadelphia kromoszóma), amely konvencionális citogenetikával a krónikus myeloid leukaemiás esetek több mint 90%-ában kimutatható, illetve a bcr-abl fúziós gén, amely tirozin-kináz-aktivitású fúziós fehérje szintézisét kódolja. Mai ismereteink alapján ez a folyamatosan aktív tirozin-kináz a krónikus myeloid leukaemia oka. Az imatinib alkalmazása jelentősen megváltoztatta a krónikus myeloid leukaemia kezelését. Az eddigi eredmények a betegség minden fázisában magas

APA, Harvard, Vancouver, ISO, and other styles

2

Allan, Norman C., and Patricia C. A. Shepherd. "Treatment of chronic myeloid leukaemia." Baillière's Clinical Haematology 1, no. 4 (1987): 1031–54. http://dx.doi.org/10.1016/s0950-3536(87)80038-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ross, David M., Sharon R. Jackson, and Peter J. Browett. "Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia." Leukemia & Lymphoma 48, no. 6 (2007): 1231–33. http://dx.doi.org/10.1080/10428190701297360.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Onoja, AM, SA Otene, AT Onoja, et al. "Prevalence and Nature of Adult Hematological Malignancies Using Bone Marrow Aspiration Cytology in a Tertiary Health Facility: A Seven Year Retrospective Review." Western Journal of Medical and Biomedical Sciences 2, no. 1 (2021): 39–45. http://dx.doi.org/10.46912/wjmbs.39.

Full text

Abstract:

Bone Marrow Aspiration (BMA) is a procedure that is often used to evaluate patients with haematological disorders including haematological malignancies (HMs) which account for about 6.5% of all cancers worldwide. There is paucity of data on the prevalence and pattern of HMs from BMA cytology in Nigeria. We carried out a retrospective review to determine the prevalence and distribution of HMs among adult patients who had BMA cytology at Benue State University Teaching Hospital (BSUTH) from June 2012 to July 2019. A total of 158 BMA reports extracted from the marrow and clinic medical records we

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Interferon gamma treatment of chronic myeloid leukaemia." Inpharma Weekly &NA;, no. 719 (1990): 6. http://dx.doi.org/10.2165/00128413-199007190-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

O'Dwyer, Michael. "First-line treatment of chronic myeloid leukaemia." Therapeutic Advances in Hematology 1, no. 1 (2010): 15–22. http://dx.doi.org/10.1177/2040620710387981.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Howard, Joshua, Benedict Mackenzie, Toby Nicholson, Sylvia Connolly, and Rishee Parmar. "A unique presentation of destructive shoulder arthropathy in the chronic phase of chronic myeloid leukaemia." Shoulder & Elbow 11, no. 3 (2017): 210–14. http://dx.doi.org/10.1177/1758573217715260.

Full text

Abstract:

We present a previously unreported case of rapidly progressing, destructive shoulder arthropathy as an initial presentation of chronic phase chronic myeloid leukaemia. This patient initially presented to clinic for consideration of an arthroplasty for symptom relief; however, her loss to follow-up yielded a rapid progression of her symptoms. Bone marrow aspirate and targeted biopsy of the humeral head excluded blast cell crisis, in contrast to previously reported cases. She was treated conservatively with medical management of her underlying disease. Although leukaemic arthritis is a recognize

APA, Harvard, Vancouver, ISO, and other styles

8

Dokic, Marina, Ivana Urosevic, Ivanka Savic, et al. "A Case of Chronic Lymphocytic Leukaemia Occurring During Treatment of Chronic Myeloid Leukaemia." Indian Journal of Hematology and Blood Transfusion 32, S1 (2016): 156–58. http://dx.doi.org/10.1007/s12288-016-0638-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Jackson, Nicholas, Ahmad Shukri, and Kamaruzaman Ali. "Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy." British Journal of Haematology 85, no. 1 (1993): 203–4. http://dx.doi.org/10.1111/j.1365-2141.1993.tb08672.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Daniels, J. M. A., A. Vonk-Noordegraaf, J. J. W. M. Janssen, P. E. Postmus, and R. van Altena. "Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia." European Respiratory Journal 33, no. 3 (2009): 670–72. http://dx.doi.org/10.1183/09031936.00025408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Goldman, John M. "Treatment of chronic myeloid leukaemia lessons and challenges." International Journal of Hematology 76, S2 (2002): 189–92. http://dx.doi.org/10.1007/bf03165116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Smith, Duncan L., John Burthem, and Anthony D. Whetton. "Molecular pathogenesis of chronic myeloid leukaemia." Expert Reviews in Molecular Medicine 5, no. 27 (2003): 1–27. http://dx.doi.org/10.1017/s1462399403006835.

Full text

Abstract:

The abnormal haemopoietic precursor cells of chronic myeloid leukaemia (CML) carry the cytogenetic abnormality [t(9;22)(q34;q11)] – a reciprocal translocation that results in the expression of a chimaeric protein derived from the fused BCR and ABL genes. This Bcr–Abl protein tyrosine kinase mediates an array of effects on signal transduction pathways affecting cell survival, proliferation, adhesion and genetic stability. The end-result of these abnormal signalling processes is a bi- or triphasic clinical disease. Initially, CML is characterised by the presence of an excess of myeloid progenito

APA, Harvard, Vancouver, ISO, and other styles

13

Uppal, Guldeep, and Jerald Gong. "Chronic neutrophilic leukaemia." Journal of Clinical Pathology 68, no. 9 (2015): 680–84. http://dx.doi.org/10.1136/jclinpath-2015-203060.

Full text

Abstract:

Chronic neutrophilic leukaemia (CNL) is a rare type of myeloproliferative neoplasm (MPN) characterised by sustained leucocytosis (≥25×109/L) with neoplastic proliferation of neutrophilic granulocytes in blood and bone marrow. In contrast to chronic myeloid leukaemia, the disease primarily involves neutrophilic lineage with persistent proliferation of mature forms of neutrophils. No consistent cytogenetic changes have been reported. Known recurrent genetic changes in other MPNs such as JAK2, MPL, CALR, BCR-ABL1, PDGFRA, PDGFRB and FGFR1 are mostly absent. Recently, mutations in colony stimulati

APA, Harvard, Vancouver, ISO, and other styles

14

Hughes, Tim, and Giuseppe Saglio. "Expert Opinion on the Treatment of Refractory Chronic Phase Chronic Myeloid Leukaemia." European Oncology & Haematology 13, no. 01 (2017): 17. http://dx.doi.org/10.17925/eoh.2017.13.01.17.

Full text

Abstract:

The development and clinical availability of second-generation tyrosine kinase inhibitors (TKIs) for the treatment of patients who discontinue imatinib therapy has further improved the outlook for patients with chronic phase chronic myeloid leukaemia (CP-CML). There is, however, uncertainty surrounding how best to treat patients after failing second-generation TKIs. A three-section questionnaire was devised by chronic myeloid leukaemia experts to address questions surrounding this issue. Responses were received from 14 out of 34 experts (41.2%). Generally, a reasonable consensus was found amon

APA, Harvard, Vancouver, ISO, and other styles

15

Latham, Susan, Paul A. Bartley, Bradley Budgen, et al. "BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia." Journal of Clinical Pathology 69, no. 9 (2016): 817–21. http://dx.doi.org/10.1136/jclinpath-2015-203538.

Full text

Abstract:

AimsRT-qPCR is used to quantify minimal residual disease (MRD) in chronic myeloid leukaemia (CML) in order to make decisions on treatment, but its results depend on the level of BCR-ABL1 expression as well as leukaemic cell number. The aims of the study were to quantify inter-individual differences in expression level, to determine the relationship between expression level and response to treatment, and to investigate the effect of expression level on interpretation of the RT-qPCR result.MethodsBCR-ABL1 expression was studied in 248 samples from 65 patients with CML by determining the differen

APA, Harvard, Vancouver, ISO, and other styles

16

Sun, Qian, Chi-Chiu So, Sze-Fai Yip, Thomas S. K. Wan, Edmond Shiu Kwan Ma, and LiChong Chan. "Functional Alterations of Lin−CD34+CD38+ Progenitors in Chronic Myelomonocytic Leukaemia and on Progression to Acute Leukaemia." Blood 110, no. 11 (2007): 4119. http://dx.doi.org/10.1182/blood.v110.11.4119.4119.

Full text

Abstract:

Abstract Chronic myelomonocytic leukaemia (CMML) is a clonal bone marrow stem cell disorder based on the presence of trilineage involvement, the association of myelodysplastic and myeloproliferative features and its ability to transform into acute myeloid leukaemia. The objectives of our study are to identify the cell population and its functional characteristics involved in evolution from CMML phase to acute myeloid leukaemia. We analysed Lin−CD34+ stem/progenitor population and performed cell proliferation, apoptotic assays, self-renewal ability and differentiation potential studies in purif

APA, Harvard, Vancouver, ISO, and other styles

17

Egyed, Miklós, Balázs Kollár, Péter Rajnics, Éva Karádi, and András Matolcsi. "Imatinib Treatment of Chronic Myeloid Leukaemia. Cohort of Patients." Hungarian Medical Journal 2, no. 4 (2008): 615–21. http://dx.doi.org/10.1556/hmj.2.2008.28354.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Goldman, John M. "New Directions for the Treatment of Chronic Myeloid Leukaemia." Drugs 49, no. 5 (1995): 651–55. http://dx.doi.org/10.2165/00003495-199549050-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Nilotinib is an effective treatment for chronic myeloid leukaemia,." Inpharma Weekly &NA;, no. 1642 (2008): 15. http://dx.doi.org/10.2165/00128413-200816420-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Goldman, John M. "Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia." Lancet 355, no. 9209 (2000): 1031–32. http://dx.doi.org/10.1016/s0140-6736(00)02029-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Singer, I. O., and I. M. Franklin. "Autografting as first line treatment for chronic myeloid leukaemia." Journal of Clinical Pathology 51, no. 2 (1998): 92–95. http://dx.doi.org/10.1136/jcp.51.2.92.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ross, David M., and Timothy P. Hughes. "Treatment-free remission in patients with chronic myeloid leukaemia." Nature Reviews Clinical Oncology 17, no. 8 (2020): 493–503. http://dx.doi.org/10.1038/s41571-020-0367-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Goldman, John M. "14 Treatment of chronic myeloid leukaemia: some topical questions." Baillière's Clinical Haematology 10, no. 2 (1997): 405–21. http://dx.doi.org/10.1016/s0950-3536(97)80015-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Druker, Brian J. "Imatinib mesylate in the treatment of chronic myeloid leukaemia." Expert Opinion on Pharmacotherapy 4, no. 6 (2003): 963–71. http://dx.doi.org/10.1517/14656566.4.6.963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Pasic, Ivan, and Jeffrey H. Lipton. "Current approach to the treatment of chronic myeloid leukaemia." Leukemia Research 55 (April 2017): 65–78. http://dx.doi.org/10.1016/j.leukres.2017.01.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kamal, SM, MA Ahad, and I. Mahmood. "Use of Imatinib Mesylate in the Management of Chronic Myeloid Le ukaemia." TAJ: Journal of Teachers Association 22, no. 2 (2009): 315–18. http://dx.doi.org/10.3329/taj.v22i2.37752.

Full text

Abstract:

lmatinib mesylate (Enliven) is a synthetic tyrosine kinase inhibitor. If inhibits the break point cluster region (BCR)-Abelson (ASL) fusion protein that results from the chromosome abnormality known as the Philadelphia chromosome which leads to increased cell proliferation in chronic myeloid leukaemia (CML). lmatinib is approved for the treatment of Philadelphia chromosome positive (Ph+ ) chronic myeloid leukaemia (CML). Response is good with high 5 years survival rate. It is well tolerated. lmatinib is also recommended for the treatment of Gastro intestinal stromal tumour (GIST), Philadelphi

APA, Harvard, Vancouver, ISO, and other styles

27

Hossain, Md Mokter, Mollah Obayedullah Baki, Tamanna E. Nur, and Zannatul Ferdous Jesmin. "Effectivity of imatinib therapy for the management of chronic myeloid leukemia patients." Bangladesh Medical Journal Khulna 51, no. 1-2 (2019): 40–43. http://dx.doi.org/10.3329/bmjk.v51i1-2.40479.

Full text

Abstract:

Background: First generation tyrosine kinase inhibitor, imatinib revolutionized the treatment of chronic myeloid leukaemia, and is now the front line therapy. Imatinib provides substantial cytogenetic and molecular remission, with minimal normal hematopoiesis suppression or side effects and is now first line therapy. Objective: The aim of this prospective study was to determine the efficacy of imatinib therapy in the management of chronic myeloid leukemia in Bangladesh. Methods: This prospective study was done from June 2012 to May 2018. In this period we treated eight chronic myel

APA, Harvard, Vancouver, ISO, and other styles

28

Rusicka, Patrycja. "Original vs generic drugs in treatment of chronic myeloid leukaemia." OncoReview 4, no. 3 (2014): 126–31. http://dx.doi.org/10.5604/20828691.1123442.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Alfayez, Mansour, Guillaume Richard‐Carpentier, Elias Jabbour, et al. "Sudden blastic transformation in treatment‐free remission chronic myeloid leukaemia." British Journal of Haematology 187, no. 4 (2019): 543–45. http://dx.doi.org/10.1111/bjh.16245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Saglio, Giuseppe, and Robert P. Gale. "Prospects for achieving treatment‐free remission in chronic myeloid leukaemia." British Journal of Haematology 190, no. 3 (2020): 318–27. http://dx.doi.org/10.1111/bjh.16506.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Allan, N. C. "Interferon-αn1, treatment benefits most patients with chronic myeloid leukaemia". Biomedicine & Pharmacotherapy 50, № 2 (1996): 93–94. http://dx.doi.org/10.1016/0753-3322(96)84724-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bund, Dagmar, Ting Yang, Raymund Buhmann, and Hans-Jochem Kolb. "Immunomodulatory Effects of STI571 in Chronic Myeloid Leukaemia." Blood 108, no. 11 (2006): 2198. http://dx.doi.org/10.1182/blood.v108.11.2198.2198.

Full text

Abstract:

Abstract Background: The tyrosine kinase inhibitor imatinib (imatinib, STI571, Glivec, and Gleevec) is highly effective in the treatment of chronic myeloid leukaemia (CML) and has already been shown to be effective in the setting of allogeneic stem cell transplantation. But until now, less is known with respect to its immunomodulating effects. Objective: In the present survey we investigated, whether imatinib could modify the antigen-presenting capacity of myeloid cells and in turn affects the cellular immune response. Method: For this purpose, patient derived chronic myeloid cells were incuba

APA, Harvard, Vancouver, ISO, and other styles

33

Newcott, Eric K., Abdallah A. Ellabban, Shokufeh Tavassoli, and Ahmed Sallam. "Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy." Case Reports in Ophthalmological Medicine 2015 (2015): 1–3. http://dx.doi.org/10.1155/2015/713868.

Full text

Abstract:

Purpose.To evaluate the efficacy of intravitreal bevacizumab and triamcinolone in the treatment of cystoid macular oedema in a case with chronic myeloid leukaemia on imatinib treatment.Methods.We treated a 78-year-old man with bilateral cystoid macular oedema with intravitreal triamcinolone and subsequent bevacizumab in one eye and intravitreal bevacizumab, alone, in the fellow eye.Results.Serial intravitreal bevacizumab with and without triamcinolone treated cystoid macular oedema in both eyes and improved the vision.Conclusion.Intravitreal bevacizumab and triamcinolone could be viable option

APA, Harvard, Vancouver, ISO, and other styles

34

Edlin, R., M. Connock, S. Tubeuf, et al. "Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia." Health Technology Assessment 14, Suppl 1 (2010): 69–74. http://dx.doi.org/10.3310/hta14suppl1-10.

Full text

Abstract:

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of azacitidine (aza) compared with conventional care regimes (CCR) for higher risk patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML), based on the evidence submission from the manufacturer to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The patient outcomes governing relative effectiveness and cost-effectiveness were defined as o

APA, Harvard, Vancouver, ISO, and other styles

35

Demeter, Judit, Anna Poros, Csaba Bödör, Laura Horváth, and Tamás Masszi. "A krónikus myeloid leukaemia korszerű diagnosztikája és kezelése." Orvosi Hetilap 157, no. 37 (2016): 1459–68. http://dx.doi.org/10.1556/650.2016.30521.

Full text

Abstract:

Chronic myelogenous leukemia is a clonal myeloproliferative neoplasm caused by reciprocal translocation involving chromosomes 9 and 22 resulting in the expression of a constitutively activated BCR-ABL1 tyrosine kinase that leads to the malignant transformation of the hematopoietic stem cells. The condition was previously known as a relentlessly progressive disease, but the treatment was revolutionalized by the efficacy of tyrosine kinase inhibitors. Therapeutic success is thus currently determined by the depth of molecular response achieved on therapy. Multiple tyrosine kinase agents are avail

APA, Harvard, Vancouver, ISO, and other styles

36

Bennour, Ayda, Nathalie Beaufils, Halima Sennana, Balkis Meddeb, Ali Saad, and Jean Gabert. "E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib." Journal of Clinical Pathology 63, no. 8 (2010): 737–40. http://dx.doi.org/10.1136/jcp.2010.078311.

Full text

Abstract:

The development of imatinib is a milestone in the treatment of chronic myeloid leukaemia (CML), and its therapeutic effect has been extensively investigated in patients with CML who carry M-bcr and m-bcrBCR–ABL fusion transcripts. However, knowledge about its therapeutic effect on patients with CML who have the rare BCR–ABL fusion transcript e19a2 (μ-bcr) remains sparse. This report describes a patient with Philadelphia-positive chronic myeloid leukaemia with e19a2 rearrangement, in whom E355G mutation had been acquired. The patient was resistant to imatinib treatment based on conventional cyt

APA, Harvard, Vancouver, ISO, and other styles

37

Ghosn, Youssef, Mohammed Hussein Kamareddine, Antonios Tawk, et al. "Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia." Technology in Cancer Research & Treatment 18 (January 1, 2019): 153303381985324. http://dx.doi.org/10.1177/1533033819853241.

Full text

Abstract:

Chronic myeloid leukemia is a myeloproliferative disease where cells of myeloid linage display a t(9;22) chromosomal translocation leading to the formation of the BCR/ABL fusion gene and the continuous activation of tyrosine kinases. This malignancy has a peak incidence at 45 to 85 years, accounting for 15% of all leukemias in adults. Controlling the activity of tyrosine kinase became the main strategy in chronic myeloid leukemia treatment, with imatinib being placed at the forefront of current treatment protocols. New approaches in future anticancer therapy are emerging with nanomedicine bein

APA, Harvard, Vancouver, ISO, and other styles

38

Cervera, Eduardo, Federico Godínez, Rosa Sosa, et al. "Mexican Guidelines for the Diagnosis and Treatment of Chronic Myeloid Leukaemia." Journal of Cancer Therapy 04, no. 03 (2013): 747–64. http://dx.doi.org/10.4236/jct.2013.43092.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Sokal, Joseph E. "Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment." Baillière's Clinical Haematology 1, no. 4 (1987): 907–29. http://dx.doi.org/10.1016/s0950-3536(87)80032-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Milojkovic, Dragana, and Jane Apperley. "State-of-the-art in the treatment of chronic myeloid leukaemia." Current Opinion in Oncology 20, no. 1 (2008): 112–21. http://dx.doi.org/10.1097/cco.0b013e3282f1fe8a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Clark, Richard E. "Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia." Leukemia Research 33, no. 9 (2009): 1151–55. http://dx.doi.org/10.1016/j.leukres.2009.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Russo, D., M. Malagola, C. Skert, et al. "Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment." Blood Cancer Journal 5, no. 9 (2015): e347-e347. http://dx.doi.org/10.1038/bcj.2015.75.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Goldman, J. M. "The treatment of chronic myeloid leukaemia-much still to be achieved." Journal of Internal Medicine 235, no. 4 (1994): 289–91. http://dx.doi.org/10.1111/j.1365-2796.1994.tb01078.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Lamure, Sylvain, Franciane Paul, Anne-Laure Gagez, et al. "A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment." Journal of Clinical Medicine 9, no. 7 (2020): 2204. http://dx.doi.org/10.3390/jcm9072204.

Full text

Abstract:

Donor lymphocyte infusion (DLI) is used to prevent or treat haematological malignancies relapse after allogeneic stem cell transplantation (allo-SCT). Recombinant human granulocyte colony-stimulated factor primed DLI (gDLI) is derived from frozen aliquots of the peripheral blood stem cell collection. We compared the efficacy and safety of gDLI and classical DLI after allo-SCT. We excluded haploidentical allo-SCT. Initial diseases were acute myeloblastic leukaemia (n = 45), myeloma (n = 38), acute lymphoblastic leukaemia (n = 20), non-Hodgkin lymphoma (n = 10), myelodysplasia (n = 8), Hodgkin l

APA, Harvard, Vancouver, ISO, and other styles

45

Kohli, Sunita, Mark Lee, and Scott Marshall. "A Case Report on the Progression of Myeloid Sarcoma to Form Multiple Metastatic Deposits without Developing Acute Myeloid Leukaemia." Case Reports in Hematology 2015 (September 30, 2015): 1–5. http://dx.doi.org/10.1155/2015/162154.

Full text

Abstract:

Introduction. Myeloid sarcomas (MS) are rare tumours occurring at extramedullary sites. They are usually associated with other haematology disorders such as acute myeloid leukaemia, myelodysplastic syndrome, and chronic myeloproliferative neoplasms. They frequently occur with a diagnosis of acute myeloid leukaemia (AML) or with relapse of preexisting disease. Patients with myeloid sarcomas without history or evidence of myeloid leukaemia typically progress to form AML. Case Presentation. A case report of a patient diagnosed with an isolated myeloid sarcoma that rarely did not transform to AML

APA, Harvard, Vancouver, ISO, and other styles

46

Menzin, Joseph, Kathleen Lang, Craig C. Earle, and Alastair Glendenning. "Treatment Patterns, Outcomes and Costs Among Elderly Patients with Chronic Myeloid Leukaemia." Drugs & Aging 21, no. 11 (2004): 737–46. http://dx.doi.org/10.2165/00002512-200421110-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Hilbe, Wolfgang, Ute Apfelbeck, Michael Fridrik та ін. "Interferon-α for the treatment of elderly patients with chronic myeloid leukaemia". Leukemia Research 22, № 10 (1998): 881–86. http://dx.doi.org/10.1016/s0145-2126(98)00064-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

MIRANDA-SILVA, WANESSA, BERNAR MONTEIRO BENITES, FELIPE PAIVA FONSECA, CAROLINA ATALLAH PONTES DA SILVA, CELSO ARRAIS-RODRIGUES, and EDUARDO RODRIGUES FREGNANI. "EXTENSIVE LICHENOID REACTION IN A PATIENT UNDER TREATMENT FOR CHRONIC MYELOID LEUKAEMIA." Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 124, no. 2 (2017): e85. http://dx.doi.org/10.1016/j.oooo.2017.05.130.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Docherty, Suzanne M., Moosavi Reza, Gillian Turner, and Kristian Bowles. "Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib." British Journal of Haematology 170, no. 6 (2015): 744. http://dx.doi.org/10.1111/bjh.13546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Mesa, Ruben A., David P. Steensma, James Hoyer, and Rhett P. Ketterling. "Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate." British Journal of Haematology 123, no. 2 (2003): 366–67. http://dx.doi.org/10.1046/j.1365-2141.2003.04607.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!